

## **A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies**

**Authors:** Caixia Li,<sup>1</sup> Jia Wei,<sup>2</sup> Keshu Zhou,<sup>3</sup> Peng Liu,<sup>4</sup> He Huang,<sup>5</sup> Fei Li,<sup>6</sup> Qingqing Cai,<sup>7</sup> Yujun Dong,<sup>8</sup> Shenmiao Yang,<sup>9</sup> Hui Zhou,<sup>10</sup> Xinyou Zhang,<sup>11</sup> Lu Zhang,<sup>12</sup> Zaixing Shi,<sup>12</sup> Zhiyu Liang,<sup>12</sup> Binghao Wu,<sup>12</sup> and Depei Wu<sup>1\*</sup>

**Affiliations:** <sup>1</sup>The First Affiliated Hospital of Soochow University, Jiangsu, China; <sup>2</sup>Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, China; <sup>3</sup>HeNan Cancer Hospital, Zhengzhou, China; <sup>4</sup>Department of Hematology, Zhongshan Hospital, Fudan University, Shanghai, China; <sup>5</sup>Zhejiang University – The First Affiliated Hospital, Hangzhou, China; <sup>6</sup>The First Affiliated Hospital of Nanchang University, Nanchang, China; <sup>7</sup>Sun Yat-Sen University Cancer Center, Guangzhou, China; <sup>8</sup>Department of Hematology, Peking University First Hospital Beijing, China; <sup>9</sup>Peking University People's Hospital, Beijing, China; <sup>10</sup>Hunan Cancer Hospital, Changsha, China; <sup>11</sup>Shenzhen People's Hospital, Shenzhen, China; and <sup>12</sup>BeiGene (Shanghai) Co., Ltd., Shanghai, China

### **ABSTRACT**

#### **Background**

BGB-11417 is a potent and highly selective Bcl-2 inhibitor. Phase 1 study results showing high activity and good tolerability in patients (pts) with mature B-cell malignancies were previously reported (Abstract 2989, ASH 2022). We present here results of BGB-11417 monotherapy in B-cell malignancies with a longer follow up.

#### **Methods**

BGB-11417-102 (NCT04883957) is an ongoing, multicenter, phase 1, open-label, dose-finding study in China. Primary objectives: safety, maximum tolerated dose (MTD), and recommended phase 2 dose (RP2D) of BGB-11417 monotherapy for selected cohorts. Pts with relapsed/refractory (R/R) B-cell malignancies received escalating doses (80, 160, 320, or 640 mg once daily) with weekly or daily ramp-up to intended target dose. Dose-limiting toxicity (DLT) for each cohort was evaluated during ramp-up through day 21 at the intended dose. AEs were reported per CTCAE v5.0 (or Grading Scale for Hematologic Toxicity in chronic lymphocytic leukemia [CLL] Studies).

#### **Results**

As of 1 Oct 2022, 54 pts (34 R/R non-Hodgkin lymphoma [NHL; 20 diffuse large B-cell lymphoma, 7 follicular lymphoma, 4 marginal zone lymphoma, 3 transformed NHL], and 20 R/R CLL/small lymphocytic lymphoma [SLL]) received ≤640 mg/d. 640mg was the highest dose pre-defined in the study and MTD was not reached. Median (range) values: age, 61 y (31-84); prior lines of systemic therapy, 2 (1-7); follow-up duration, 6.6 m (0.2-13.0). Study discontinuation: 23

pts (22 NHL; 1 CLL/SLL); reasons: 18 progressive disease, 4 withdrew, 1 investigator decision. Tx-emergent AEs (TEAEs): all grades, 92.6%; grade  $\geq 3$ , 53.7%. Most common TEAE: all grades, white blood cell count decreased (48.1%); grade  $\geq 3$ , neutropenia (25.9%). DLTs occurred in 3 patients at 80 mg/d or 160 mg/d; 14.8% had serious TEAEs and 14.8% had TEAEs leading to drug interruption. No pts had TEAEs leading to death/tx discontinuation or clinical tumor-lysis syndrome events. Of 39 pts available for tumor assessment (27 NHL; 12 CLL/SLL), 5 with NHL and 9 with CLL/SLL achieved responses (NHL: 3 partial responses [PR] at 160 mg/d, 1 PR at 320 mg/d, 1 complete response [CR] at 640 mg/d; CLL/SLL: 2 CR and 2 PR at 80 mg/d, 3 PR at 160 mg/d, 2 PR at 320 mg/d). Nine pts with R/R CLL/SLL (5 at 80mg/d, 4 at 160 mg/d) had minimum residual disease (MRD) assessment; 3 had undetectable MRD with CLL cell/total nucleated cells  $<10^{-4}$  (uMRD4; 1 pt achieved blood and bone marrow aspirate uMRD4 after 4.5 months at 80 mg/d; 2 pts had blood uMRD4 after 7.1 months at 160 mg/d). The monotherapy RP2D for R/R CLL/SLL was 320 mg/d.

### **Conclusion**

These results demonstrated that BGB-11417 monotherapy was well tolerated at all tested doses up to 640 mg/d, with no dose-dependent toxicity increase. BGB-11417 monotherapy showed promising initial efficacy results in R/R CLL/SLL, with pts achieving responses at lower dose levels.